Drug Profile
ES 135
Alternative Names: EUSOL-rhFGF1Latest Information Update: 05 May 2023
Price :
$50
*
At a glance
- Originator Eusol Biotech
- Class Fibroblast growth factors; Peptides; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Spinal cord injuries
Most Recent Events
- 20 Apr 2023 Eusol Biotech suspends a phase III trial in Spinal cord injuries in Taiwan (Intrathecal) due to low recruitment rate (NCT03229031)
- 18 Mar 2021 Phase III development is ongoing in Taiwan (Eusol Biotech, March 2021)
- 20 Apr 2018 Eusol Biotech has patent protection for ES 135 IN Taiwan, EU, China and USA (Eusol Biotech, April 2018)